Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2017 Financial Results and Conference Call
26 janv. 2017 04h05 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal third quarter 2017, ended...
Oculus Innovative Sciences Announces Corporate Name Change to Sonoma Pharmaceuticals, Inc. and New NASDAQ Ticker Symbol to Better Align with Dermatology Focus
05 déc. 2016 05h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the...
Oculus Innovative Sciences Reports Financial Results for Fiscal Second Quarter 2017
10 nov. 2016 16h05 HE
|
Oculus Innovative Sciences, Inc.
U.S. Product Revenue up 43%, Driven by Growth in U.S. Dermatology Oculus Announced Sale of Latin America Assets for $19.5 Million in Cash (see separate press release, issued on October 31,...
Oculus Innovative Sciences Sells Latin America Business to Invekra S.A.P.I. de C.V. for $19.5 Million in Cash
31 oct. 2016 16h05 HE
|
Oculus Innovative Sciences, Inc.
Total cash consideration for sale of Latin American business (which is 30% of current Oculus revenue) exceeds Oculus’ current market capitalization of $17 million U.S.Transaction further includes...
Oculus Innovative Sciences Announces Fiscal Second Quarter 2017 Financial Results and Conference Call
27 oct. 2016 04h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal second quarter 2017,...
Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
30 août 2016 04h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
24 août 2016 05h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the...
Oculus Innovative Sciences Receives Australian Approvals to Market Sterile Microcyn®-Based Antimicrobial Solutions and Hydrogel Dressings
11 août 2016 04h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets unique and...
Oculus Innovative Sciences Reports Financial Results for First Quarter of Fiscal Year 2017
28 juil. 2016 16h05 HE
|
Oculus Innovative Sciences, Inc.
Product Revenue Up 20% Driven by Growth in U.S. Dermatology Dermatology Prescriptions Up 37%, June Quarter over March 2016 Quarter Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif.,...
Oculus Innovative Sciences Announces Fiscal First Quarter 2017 Financial Results and Conference Call
19 juil. 2016 04h05 HE
|
Oculus Innovative Sciences, Inc.
PETALUMA, Calif., July 19, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: OCLS, warrants OCLSW), today announced that the financial results for its fiscal first quarter 2017,...